Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,612 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 3,662 · Balance 75,612 F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Kenneth C. Anderson 2021 Irrevocable Trust | 129,877 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 129,877 F3: Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Kenneth C. Anderson 2015 Irrevocable Trust | 74,581 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 74,581 F4: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Cynthia E. Anderson 2015 Irrevocable Trust | 74,581 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 74,581 F5: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Kenneth C. Anderson Revocable Trust | 3,623 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,623 F6: Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Cynthia E. Anderson Revocable Trust | 3,623 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 3,623 F7: Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026.
F3: Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F4: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F5: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F6: Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F7: Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:43 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 3,662 | $3.14 | $11,498.68 |
DisclosureSEC source: 0001470831-26-000925 · wk-form4_1790973827.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,612 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 2,650 | $4.34 | $11,501.00 |
DisclosureSEC source: 0001470831-26-000688 · wk-form4_1783022665.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,950 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001470831-26-000665 · wk-form4_1782505819.xml · derivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 20:14 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,070 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001470831-26-000504 · wk-form4_1780604078.xml · derivative · entry 7 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,070 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction represents the exercise of a stock option for cash. No shares were sold in connection with the exercise. F7 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 20:14 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 1,070 | $2.11 | $2,257.70 |
DisclosureSEC source: 0001470831-26-000504 · wk-form4_1780604078.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction represents the exercise of a stock option for cash. No shares were sold in connection with the exercise. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 14:45 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 4,259 | $2.70 | $11,499.30 |
DisclosureSEC source: 0001470831-26-000346 · wk-form4_1775227552.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,230 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2026. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 5,958 | $1.93 | $11,498.94 |
DisclosureSEC source: 0001470831-26-000009 · wk-form4_1767647442.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,532 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2026. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:14 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 5,349 | $2.15 | $11,500.35 |
DisclosureSEC source: 0001470831-25-000250 · wk-form4_1759522454.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,574 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 7,616 | $1.51 | $11,500.16 |
DisclosureSEC source: 0001662579-25-000053 · wk-form4_1751487429.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,225 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2025. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 35,500 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001662579-25-000046 · wk-form4_1750450283.xml · derivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 35,500 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 7,841 | $1.44 | $11,251.84 |
DisclosureSEC source: 0001662579-25-000024 · wk-form4_1743711094.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,609 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 3,074 | $3.66 | $11,250.84 |
DisclosureSEC source: 0001662579-25-000003 · wk-form4_1735938496.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,768 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2025. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:32 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 2,023 | $5.56 | $11,247.88 |
DisclosureSEC source: 0001662579-24-000089 · wk-form4_1727901140.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,694 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2024. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 2,320 | $4.85 | $11,252.00 |
DisclosureSEC source: 0001662579-24-000063 · wk-form4_1719951170.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,671 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2024. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:07 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001662579-24-000055 · wk-form4_1719000414.xml · derivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-06-19 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,389 | $8.10 | $11,250.90 |
DisclosureSEC source: 0001662579-24-000038 · wk-form4_1712090101.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,351 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2024. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,725 | $6.52 | $11,247.00 |
DisclosureSEC source: 0001662579-24-000005 · wk-form4_1704316284.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,962 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2024. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 6,617 | $1.70 | $11,248.90 |
DisclosureSEC source: 0001662579-23-000109 · wk-form4_1696364878.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,237 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 2, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:25 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 3,976 | $2.83 | $11,252.08 |
DisclosureSEC source: 0001662579-23-000068 · wk-form4_1688588720.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,620 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 3, 2023. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:25 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000062 · wk-form4_1686947141.xml · derivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:19 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 3,516 | $3.20 | $11,251.20 |
DisclosureSEC source: 0001662579-23-000045 · wf-form4_168063954562598.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,644 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 3, 2023. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 444 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001662579-23-000008 · wf-form4_167304210044893.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890 Underlying: Common Stock · 444 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option vest and become exercisable in 12 equal quarterly installments, with the first installment vested on October 1, 2020. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 268 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001662579-23-000008 · wf-form4_167304210044893.xml · derivative · entry 8 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067 Underlying: Common Stock · 268 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 12.5% of the shares underlying this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 444 | $4.98 | $2,211.12 |
DisclosureSEC source: 0001662579-23-000008 · wf-form4_167304210044893.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 268 | $2.11 | $565.48 |
DisclosureSEC source: 0001662579-23-000008 · wf-form4_167304210044893.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,568 | $6.38 | $10,003.84 |
DisclosureSEC source: 0001662579-23-000006 · wf-form4_167286703601250.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,416 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 3, 2023. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 445 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · derivative · entry 10 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334 Underlying: Common Stock · 445 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares underlying this option vest and become exercisable in 12 equal quarterly installments, with the first installment vested on October 1, 2020. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 267 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,335 Underlying: Common Stock · 267 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 12.5% of the shares underlying this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,150 | $8.69 | $9,993.50 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · nonDerivative · entry 3 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,848 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 3, 2022. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 445 | $4.98 | $2,216.10 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 267 | $2.11 | $563.37 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 21:18 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 889 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-22-042457 · doc4.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,779 Underlying: Common Stock · 889 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option vest and become exercisable in 12 equal quarterly installments, with the first installment vested on October 1, 2020. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 21:18 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 535 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-22-042457 · doc4.xml · derivative · entry 8 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,602 Underlying: Common Stock · 535 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 12.5% of the shares underlying this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 21:18 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 889 | $4.98 | $4,427.22 |
DisclosureSEC source: 0001209191-22-042457 · doc4.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 21:18 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 535 | $2.11 | $1,128.85 |
DisclosureSEC source: 0001209191-22-042457 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,246 | $8.03 | $10,005.38 |
DisclosureSEC source: 0001209191-22-040597 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,562 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2022. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 20:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001209191-22-038865 · doc4.xml · derivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:25 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 341 | $26.46 | $9,022.86 |
DisclosureSEC source: 0001209191-22-023016 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,316 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 4, 2022. Read SEC document |
| January 26, 2022 Filed Jan 26, 2022 22:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,334 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-22-005107 · doc4.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,668 Underlying: Common Stock · 1,334 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option vest and become exercisable in 12 equal quarterly installments, with the first installment vested on October 1, 2020. Read SEC document |
| January 26, 2022 Filed Jan 26, 2022 22:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 803 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-22-005107 · doc4.xml · derivative · entry 8 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,137 Underlying: Common Stock · 803 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 12.5% of the shares underlying this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| January 26, 2022 Filed Jan 26, 2022 22:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 1,334 | $4.98 | $6,643.32 |
DisclosureSEC source: 0001209191-22-005107 · doc4.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2022 Filed Jan 26, 2022 22:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 803 | $2.11 | $1,694.33 |
DisclosureSEC source: 0001209191-22-005107 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2022 Filed Jan 18, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 278 | $31.58 | $8,779.24 |
DisclosureSEC source: 0001209191-22-003500 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,838 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 4, 2022. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 20:53 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 194 | $44.99 | $8,728.06 |
DisclosureSEC source: 0001209191-21-059515 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,560 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 4, 2021. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 220 | $39.72 | $8,738.40 |
DisclosureSEC source: 0001209191-21-045806 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,366 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 2, 2021. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001209191-21-041427 · doc4.xml · derivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2022 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 14, 2021 Filed Apr 14, 2021 20:39 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 444 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-21-026665 · doc4.xml · derivative · entry 10 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,002 Underlying: Common Stock · 444 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Represents underlying unexercised options that were granted on July 3, 2020. The terms of the original grant provide that this option shall vest and become exercisable in 12 equal quarterly installments, with the first installment vested on October 1, 2020. Read SEC document |
| April 14, 2021 Filed Apr 14, 2021 20:39 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 267 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-21-026665 · doc4.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,940 Underlying: Common Stock · 267 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 12.5% of this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| April 14, 2021 Filed Apr 14, 2021 20:39 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 444 | $4.98 | $2,211.12 |
DisclosureSEC source: 0001209191-21-026665 · doc4.xml · nonDerivative · entry 4 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2021 Filed Apr 14, 2021 20:39 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 267 | $2.11 | $563.37 |
DisclosureSEC source: 0001209191-21-026665 · doc4.xml · nonDerivative · entry 3 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.